Join

Compare · ARGX vs IMRA

ARGX vs IMRA

Side-by-side comparison of argenx SE (ARGX) and IMARA Inc. (IMRA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ARGX and IMRA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • ARGX is the larger of the two at $53.41B, about 1472.9x IMRA ($36.3M).
  • Over the past year, ARGX is up 52.1% and IMRA is down 69.6% - ARGX leads by 121.7 points.
  • Both names hit the wire about 1 times in the past 4 weeks.
  • ARGX has more recent analyst coverage (25 ratings vs 3 for IMRA).
PerformanceARGX+52.05%IMRA-69.64%
2025-07-21+0.00%2026-07-17
MetricARGXIMRA
Company
argenx SE
IMARA Inc.
Price
$861.30+0.30%
$15.20-1.36%
Market cap
$53.41B
$36.3M
1M return
-1.91%
-12.74%
1Y return
+52.05%
-69.64%
Sector
Health Care
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2017
2020
News (4w)
1
1
Recent ratings
25
3
ARGX

argenx SE

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

IMRA

IMARA Inc.

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Latest ARGX

Latest IMRA